Scientific Programme
Day 1 | Tuesday, 2 May 2023
| From 7:30 a.m. | Registration Counter open | |
| 09:00 - 09:30 a.m. | Opening remarks | Klaus Pantel, Germany & Catherine Alix-Panabières, France |
| Welcome address of the dean of the University Medical Centre Hamburg | Blanche Schwappach-Pignataro, Germany | |
| Session 1 | Cancer Biology | Chairs: Catherine Alix-Panabières, France Christoph Wagener, Germany |
| 09:30 - 10:00 a.m. | Mechanisms of Metastatic Awakening | Robert Weinberg, USA |
| 10:00 - 10:30 a.m. | Circulating Tumor Cell Clusters | Nicola Aceto, Switzerland |
| 10:30 - 11:00 a.m. | Tumor-derived extracellular vesicle DNA: novel configuration and immune regulation in cancer | David Lyden, USA |
| 11:00 - 11:15 a.m. | Understanding the biomechanics of colon metastasis-competent CTCs using microchips mimicking microcapillaries of the bloodstream | Keerthi Kurma, France |
| 11:15 - 11:30 a.m. | Deciphering the methylation signature of circulating extracellular vesicle DNA and cell-free DNA for CNS tumor classification | Franz Ricklefs, Germany |
| 11:30 - 11:45 a.m. | Coffee Break | |
| Session 2 | Cancer Immunology | Chairs: Klaus Pantel, Germany Samuel Huber, Germany |
| 11:45 a.m. - 12:30 p.m. | Insights from a thirty-year journey of PD-1: function, regulation and therapeutic modulation | Keynote by Tasuko Honjo, Nobel Laureate 2018, Japan |
| 12:30 - 01:00 p.m. | Gut microbiota fingerprint predicting resistance to cancer immunotherapy | Laurence Zitvogel, France |
| 01:00 - 01:15 p.m. | Treatment response monitoring using cell-free DNA fragmentation profiling | Remond Fijneman, The Netherlands |
| 01:15 - 01:30 p.m. | Single cell transcriptome atlas reveals a high degree of hetereogeneity in NSCLC circulating tumor cells | Melanie Janning, Germany |
| 01:30 - 02:45 p.m. | Lunch Break | |
| Session 3 | Liquid Biopsy-Based Detection of Primary Cancer & Minimal Residual Cancer – Part I | Chairs: Nikolas von Bubnoff, Germany Stefan Schneider, Germany |
| 02:45 - 03:15 p.m. | Clinical applications of MRD | Nickolas Papadopoulos, USA |
| 03:15 - 03:45 p.m. | Liquid Biopsy: From Discovery to Clinical implementation | Klaus Pantel, Germany |
| 03:45 - 04:00 p.m. | A whole leukocyte-DNA methylome risk score to predict pancreatic cancer | Evangelina López De Maturana, Spain |
| 04:00 - 04:15 p.m. | A data-driven approach employing automated Machine Learning reveals novel liquid biopsy methylation biomarkers for breast cancer | Ekaterini Alexiou Chatzaki, Greece |
| 04:15 - 06:15 p.m. | Poster Session with Coffee | |
Day 2 | Wednesday, 3 May 2023
| Session 4 | Liquid Biopsy and Immuno-Oncology | Chairs: Christoffer Gebhardt, Germany Paul Hofman, France |
| 09:00 - 09:30 a.m. | Targeting mismatch repair with immunotherapy | Luis Diaz, USA |
| 09:30 - 10:00 a.m. | The power of circulating tumor cells in Immuno-Oncology | Catherine Alix-Panabières, France |
| 10:00 - 10:15 a.m. | Circulating cell-free DNA and circulating tumor cells as prognostic biomarkers in stage III melanoma | Anthony Lucci, USA |
| 10:15 - 10:30 a.m. | Circulating tumor DNA (ctDNA) as sensitive and specific biomarker in stage I to III malignant melanoma | Eva Dazert-Klebsattel, Germany |
| 10:30 - 11:00 a.m. | Coffee Break | |
| Session 5 | Immunotherapy for Prevention of Metastatic Progression – Part I | Chairs: Katja Weisel, Germany Laurence Zitvogel, France |
| 11:00 - 11:30 a.m. | Harnessing Natural Killer cells in cancer | Eric Vivier, France |
| 11:30 a.m. - 12:00 p.m. | Claudin6-directed therapy approaches in solid tumors | Carsten Bokemeyer, Germany |
| 12:00 - 12:15 p.m. | Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma CTCs in a murine xenotransplantation model and alters metabolic pathways | Daniel J. Smit, Germany |
| 12:15 - 12:30 p.m. | Circulating tumor cell enumeration and ultradeep T-cell receptor- sequencing in a Phase I clinical trial of metastatic prostate cancer | Karl-Henning Kalland, Norway |
| 12:30 - 02:00 p.m. | Lunch Break | |
| Session 6 | Liquid Biopsy-Based Detection of Primary Cancer & Minimal Residual Cancer – Part II | Chairs: Matthias Löhr, Sweden Thilo Hackert, Germany |
| 02:00 - 02:30 p.m. | Pushing the boundaries to expand diagnostic applications of circulating DNA | Nitzan Rosenfeld, UK |
| 02:30 - 03:00 p.m. | Integration of liquid biopsies into molecular tumor boards | Ellen Heitzer, Austria |
| 03:00- 03:30 p.m. | Circulating Tumor DNA for Minimal Residual Disease Detection and Risk-Stratified Recurrence Surveillance in Colorectal Cancer | Claus Lindbjerg Andersen, Denmark |
| 03:30 - 03:45 p.m. | Potential clinical utility of circulating tumor DNA detected by digital PCR in anationwide Danish cohort of high-risk colorectal cancer patients | Tenna Henriksen, Denmark |
| 03:45 - 04:00 p.m. | Personalised analysis of cell-free circulating tumour DNA for detection of molecular residual disease and recurrence in patients with head and neck squamous cell carcinoma: the LIONESS study | Susanne Flach, Germany |
| 04:00 - 04:30 p.m. | Rita Zamarchi Award Session | Chair: Maria Chiara Scaini, Italy |
| 04:30 - 06:30 p.m. | Poster Session with Coffee | |
Day 3 | Thursday, 4 May 2023
| Session 7 | Latest developments in Liquid biopsy-based monitoring of MRD | Chairs: Ellen Heitzer, Austria Claus Lindbjerg Andersen, Denmark |
| 09:00 - 09:20 a.m. | Screening of patient samples with advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA using Three Targeted Assays | Lea Payen, France |
| 09:20 - 09:40 a.m. | Standardizing and harmonizing MRD assessment using ctDNA to enable clinical implementation to improve patient outcomes | Mohan Bolisetty, USA |
| 09:40 - 10:00 a.m. | Comprehensive liquid biopsy analysis as a tool for early detection of minimal residual disease in breast cancer | Athina Markou, Greece |
| 10:00 - 10:30 a.m. | Coffee Break | |
| Session 8 | Immunotherapy for prevention of metastatic progression – Part II | Chairs: Simon Joosse, Germany Gunhild von Amsberg, Germany |
| 10:30 - 11:00 a.m. | Immunotherapy of Lung Cancer – Current Status in metastatic and non-metastatic NSCLC | Martin Reck, Germany |
| 11:00 - 11:30 a.m. | Liquid biopsy & lung cancer immunotherapy: Between hope and hype in routine practice | Paul Hofman, France |
| 11:30 a.m. - 12:00 p.m. | Omics-driven identification of therapeutic resistance in metastatic melanoma patients receiving immune checkpoint inhibition | Christoffer Gebhardt, Germany |
| 12:00 - 12:30 p.m. | Outlook of clinical applications of Liquid Biopsy | Howard Scher, USA |
| 12:30 - 01:00 p.m. | Young Investigator Awards | |
| 01:00 - 01:15 p.m. | Concluding Remarks | Klaus Pantel, Germany & Catherine Alix-Panabières, France |